Overview

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Status:
Completed

Trial end date:
2020-04-01

Target enrollment:

Participant gender:

Summary

The investigators plan to investigate AFM13 and evaluate its ability to facilitate and redirect the Natural Killer (NK) cells in eliminating CD30-positive lymphoma targets in the skin and, by inference, other organs involved by the lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ahmed Sawas

Treatments:

Antibodies
Immunoglobulins